Systemic and ophthalmic manifestations of West Nile virus infection

Expert Review of Ophthalmology

Volumn 3, Issue 3, 2008, Pages 279-292

  Priestley, Yos ^a   Thiel, Marcia ^a   Koevary, Steven B ^a  

^a NEW ENGLAND COLLEGE OF OPTOMETRY   (United States)

Author keywords

Anterior uveitis; Chorioretinitis; Encephalitis; Meningitis; Optic neuritis; Retinal vasculities; Vitritis; West Nile virus

Indexed keywords

ALPHA2B INTERFERON; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHIMERIVAX; DIETHYLTOLUAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INFUSION FLUID; INSECT REPELLENT; LIVE VACCINE; MINOCYCLINE; PREDNISOLONE; PREDNISOLONE ACETATE; RIBAVIRIN; STEROID; VIRUS PROTEIN; WEST NILE VACCINE;

ABDUCENS NERVE PARALYSIS; ADULT; AGED; ASSISTED VENTILATION; BLOOD TRANSFUSION; BLURRED VISION; CASE REPORT; CELLULAR IMMUNITY; CHORIORETINITIS; CHORIORETINOPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CORNEA REFLEX; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DISEASE CARRIER; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; EYELID EDEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GEOGRAPHIC DISTRIBUTION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION RISK; INTENSIVE CARE; IRIDOCYCLITIS; LONG TERM CARE; MALAISE; MASS IMMUNIZATION; MORBIDITY; MORTALITY; MUSCLE DISEASE; MYALGIA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NYSTAGMUS; OCCUPATIONAL THERAPY; ONSET AGE; OPTIC NEURITIS; ORGAN DONOR; PHYSIOTHERAPY; PROGNOSIS; PROTECTIVE CLOTHING; RETINA VASCULITIS; REVERSE TRANSCRIPTION; REVIEW; RISK REDUCTION; SECONDARY INFECTION; SERODIAGNOSIS; SINGLE DRUG DOSE; SPEECH THERAPY; UVEITIS; VIRUS INFECTION; VIRUS TRANSMISSION; VISUAL ACUITY; VISUAL FIELD DEFECT; WATER CONTAMINATION; WEST NILE ENCEPHALITIS; WEST NILE FLAVIVIRUS; WEST NILE MENINGITIS; WEST NILE POLIOMYELITIS; WEST NILE VIRUS INFECTION;

EID: 47249114842     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.3.3.279     Document Type: Review

References (91)

1. Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, Roehrig JT. Use of immunoglobulin M cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin. Diagn. Lab. Immunol. 9, 544-549 (2002).
2. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11, 1174-1179 (2005).
3. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am: J. Trop. Med. 20, 471-492 (1940).
4. Nash D, Mostashari F, Fine A et al.; 1999 West Nile Outbreak Response Working Group. The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344, 1807-1814 (2001).
5. Lanciotti RS, Roehrig JT, Deubel V et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286, 2333-2337 (1999).
6. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann. Intern. Med. 137, 173-179 (2002).
7. O'Leary DR, Marfin AA, Montgomery SP et al. The epidemic of West Nile Virus in the United States, 2002. Vector Borne Zoonotic. Dis. 4, 61-70 (2004).
8. Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin. Proc. 78, 1137-1143 (2003).
9. Batsis JA, Phy MP. West Nile virus meningitis in a chronic immunosuppressed patient with rheumatoid arthritis. Clin. Rheumatol. 24, 548-550 (2005).
10. Batalis NI, Galup L, Zaki SR, Prahlow JA. West Nile virus encephalitis. Am. J. Forensic Med. Pathol. 26, 192-196 (2005).
11. Bode AV, Sejvar JJ, Pape WJ, Campbell GL, Marfin AA. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin. Infect. Dis. 42, 1234-1240 (2006).
12. Khairallah M, Ben Yahia S, Attia S, Jelliti B, Zaouali S, Ladjimi A. Severe ischemic maculopathy in a patient with West Nile virus infection. Ophthalmic. Surg. Lasers Imaging 37, 240-242 (2006).
13. Berner YN, Lang R, Chowers MY. Outcome of West Nile fever in older adults. J. Am. Geriatr. Soc. 50, 1844-1846 (2002).
14. Chowers MY, Lang R, Nassar et al. Clinical characteristics of West Nile fever outbreak, Israel 2000. Emerg. Infect. Dis. 7, 675-678 (2001).
15. LaBeaud AD, Kile JR, Kippes C, King CH, Mandalakas AM. Exposure to West Nile virus during the 2002 epidemic in Cuyahoga County, Ohio: a comparison of pediatric and adult behaviors. Public Health Rep. 122, 356-361 (2007).
16. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
17. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203, 35-40 (2006).
18. Diamond MS, Klein RS. A genetic basis for human susceptibility to West Nile virus. Trends Microbiol. 14(7), 287-289 (2006).
19. Kramer LD, Li J, Shi PY. West Nile virus. Lancet Neurol. 6, 171-181 (2007).
20. Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, Gordon SM. West Nile virus infection: a new acute paralytic illness. Neurology 61, 55-59 (2003).
21. Sejvar JJ, Haddad MB, Tierney BC et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 290, 511-515 (2003).
22. Samuel MA. Diamond MS. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80, 9349-9360 (2006).
23. Diamond MS, Shrestha B, Mehlhop E et al. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol. 16, 259-278 (2003).
24. Wang T, Town T, Alexopoulou L et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10, 1366-1373 (2004).
25. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77, 2578-2586 (2003).
26. Fredericksen BL, Smith M, Katze MG, Shi PY, Gale M Jr. The host response to West Nile Virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78, 7737-7747 (2004).
27. Cinatl J Jr, Michaelis M, Fleckenstein C et al. West Nile virus infection induces interferon signalling in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 47, 645-651 (2006).
28. Kramer LD, Li J, Shi PY. West Nile virus. Lancet Neurol. 6, 171-181 (2007).
29. Garg S, Jampol LM. Systemic and intraocular manifestations of West Mile virus infection. Surv. Ophthalmol. 50(1), 3-13. (2005).
30. Iwamoto M, Jernigan DB, Guasch A et al. Transmission of West Nile virus from organ donor to four transplant recipients. N. Engl. J. Med. 348, 2196-2203 (2003).
31. Centers for Disease Control and Prevention. West Nile Virus infections in organ transplant receipients - New York and Pennsylvania, August-September, 2005. MMWR Morb. Mortal. Wkly Rep. 54, 1021-1023 (2005).
32. Harrington T, Kuehnert MJ, Kamel H et al. West Nile virus infection transmitted by blood transfusion. Transfusion 43, 1018-1022 (2003).
33. Pealer LN, Marfin AA, Petersen LR et al. West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 349, 1236-1245 (2003).
34. Alpert SG, Fergerson J, Noel LP. Intrauterine West Nile virus: ocular and systemic findings. Am. J. Ophthalmol. 136, 733-735 (2003).
35. O'Leary DR, Kuhn S, Kniss KL et al. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics 117, e537-e545 (2006).
36. Fradin MS, Day JF. Comparative efficacy of insect repellants against mosquito bites. N. Engl. J. Med. 347, 13-18 (2002).
37. Centers for Disease Control and Prevention (CDC). West Mile virus activity - United States, 2006. MMWR Morb. Mortal. Wlky Rep. 56, 556-559 (2007).
38. Hayes EB, Gubler DJ. West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States. Annu. Rev. Med. 57, 181-194 (2006).
39. Peterson LR, Marfin AA. Gubler DJ. West Nile Virus. JAMA 290, 524-528 (2003).
40. Nasci RS, Savage HM, White DJ et al. We Nile virus in overwintering Culex mosquitoes, New York City, 2000. Emerg. Infect. Dis. 7, 742-744 (2001).
41. Rimon A, Straussberg R, Amir J. West Nile encephalitis mimicking herpes encephalitis. Pediatr. Neurol. 35, 62-64 (2006).
42. Francisco AM, Glaser C, Frykman E et al. 2004 California pediatric West Nile virus case series. Pediatr. Infect. Dis. J. 25, 81-84 (2006).
43. Tilley PA, Fox JD, Jayaraman GC, Preiksaitis JK. Maculopapular rash and tremor are associated with West Nile fever and neurological syndromes. J. Neurol. Neurosurg. Psychiatry 78, 529-531 (2007).
44. Jesitus, John. West Nile virus skin symptoms documented. Dermatol. Times 18, 22 (2005).
45. Watson JT, Pertel PE, Jones RC et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann. Intern. Med. 141, 360-365 (2004).
46. Klee AL, Maidin B, Edwin B et al. Long-term prognosis for clinical West Nile virus infection. Emerg. Infect. Dis. 10, 1405-1411 (2004).
47. Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin. Infect. Dis. 44, 1617-1624 (2007).
48. Rosas H, Wippold FJ II. West Nile virus: case report with MR imaging findings. Am. J. Neuroradiol. 24, 1376-1378 (2003).
49. Sejvar JJ, Bode AV, Marfin AA et al. West virus-associated flaccid paralysis. Emerg. Infect. Dis. 11, 1021-1027 (2005).
50. Sejvar JJ, Bode AV, Marfin AA et al. West Nile virus-associated flaccid paralysis outcome. Emerg. Infect. Dis. 12, 514-516 (2006).
51. Leis AA, Stokic DS, Webb RM, Slavinski SA, Fratkin J. Clinical spectrum of muscle weakness in human West Nile virus infection. Ann. Neurol. 28, 302-308 (2003).
52. Li J, Loeb JA, Shy ME et al. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann. Neurol. 53, 703-710 (2003).
53. Schafernak KT, Bigio EH. West Nile virus encephalomyelitis with polio-like paralysis and nigral degeneration. Can. J. Neurol. Sci. 33, 407-410 (2006).
54. Ahmed S, Libman R, Wesson K, Ahmed F, Einberg K. Guillain-Barré syndrome: an unusual presentation of West Nile virus infection. Neurology 55, 144-146. (2000).
55. Cao N, Ranganathan C, Kupsy W, Li J. Recovery and prognosticators of paralysis in West Nile virus infection. J. Neurol. Sci. 236, 73-80 (2005).
56. Cunha BA, Eisenstein LE, Wirkowski E, Klein NH, Johnson DH. West Nile encephalitis relapse presenting with abducens and facial nerve palsies. Am. J. Med. 119, e1-e2 (2006).
57. Cunha BA, Thermidor M, Mohan S, Ly H. West Nile viral encephalitis mimicking hepatic encephalopathy. Heart Lung 34, 72-75 (2005).
58. Jamison SC, Michaels SR, Ratard R, Sweet JM, Deboisblanc BP. A 41-year-old HIV-positive man with acute onset of quadriplegia after West Nile virus infection. South Med. J. 100, 1051-1053(2007).
59. Paddock CD, Nicholson WL, Bhatnagar J et al. Fatal hemorrhagic fever caused by West Nile virus in the United States. Clin. Infect. Dis. 42, 1527-1535 (2006).
60. Chan CK, Limstrom SA, Tarasewicz DG, Lin SG. Ocular features of west nile virus infection in North America: a study of 14 eyes. Ophthalmology 113, 1539-1546 (2006).
61. Bakri SJ, Kaiser PK. Ocular manifestations of West Nile virus. Curr. Opin. Ophthalmol. 15, 537-540 (2004).
62. Khairallah M, Ben Yahia S, Ladjimi A et al. Chorioretinal involvement in patients with West Nile virus infection. Ophthalmology 111, 2065-2070 (2004).
63. Hershberger VS, Augsburger JJ, Hutchins RK, Miller SA, Horwitz JA, Bergmann M. Chorioretinal lesions in nonfatal cases of West Nile virus infection. Ophthalmology 110, 1732-1736 (2003).
64. Anninger W, Lubow M. Visual loss with West Nile virus infection: a wider spectrum of a 'new' disease. Clin. Infect. Dis. 38, e55-e56. (2004).
65. Myers JP, Leveque TK, Johnson MW. Extensive chorioretinitis and severe vision loss associated with West Nile virus meningoencephalitis. Arch. Ophthalmol. 123, 1754-1756 (2005).
66. Khairallah M, Ben Yahia S, Atria S et al. Indocyanine green angiographic features in multifocal chorioretinitis associated with West Nile virus infection. Retina 26, 358-359 (2006).
67. Khairallah M, Ben Yahia S, Attia S, Zaouali S, Ladjimi A, Messaoud R. Linear pattern of West Nile virus-associated chorioretinitis is related to retinal nerve fibres organization. Eye 21, 952-955 (2007).
68. Khairallah M, Ben Yahia S, Letaief M et al. A prospective evaluation of factors associated with chorioretinitis in patients with West Nile virus infection. Ocul. Immunol. Inflamm. 15, 435-439 (2007).
69. Bains HS, Jampol LM, Caughron MC, Parnell JR. Vitritis and chorioretinitis in a patient with West Nile virus infection. Arch. Ophthalmol. 121, 205-207. (2003).
70. Yim R, Posfay-Barbe KM, Nolt D, Fatula G, Wald ER. Spectrum of clinical manifestations of West Nile virus infection in children. Pediatrics 114, 1673-1675 (2004).
71. Kuchtey RW, Kosmorsky GS, Martin D, Lee MS. Uveitis associated with West Nile virus infection. Arch. Ophthalmol. 121, 1648-1649 (2003).
72. Teitelbaum BA, Newman TL, Tresley DJ. Occlusive retinal vasculitis in a patient with West Nile virus. Clin. Exp. Optom. 90, 463-467 (2007).
73. Kaiser PK, Lee MS, Martin DA. Occlusive vasculitis in a patient with concomitant West Nile virus infection. Am. J. Ophthalmol. 136, 928-930 (2003).
74. Gilad R, Lampl Y, Sadeh M, Paul M, Dan M. Optic neuritis complicating west nile virus meningitis in a young adult. Infection 31, 55-56 (2003).
75. Abroug F, Ouanes-Besbes L, Letaief M et al. A cluster study of predictors of severe West Nile virus infection. Mayo Clin. Proc. 81, 12-16 (2006).
76. Wolfensberger TJ, Herbort CP Indocyanine green angiographic features in ocular sarcoidosis. Ophthalmology 106, 285-289 (1999).
77. Gass JD, Braunstein RA, Chenoweth RG Acute syphilitic placoid chorioretinitis. Ophthalmology 97, 1288-1297 (1990).
78. Thompson MJ, Albert DM. Ocular tuberculosis. Arch. Ophthalmol. 123, 844-849 (2005).
79. Rao N, Char D, Gnatz S. Rehabilitation outcomes of 5 patients with severe West Nile virus infection: a case series. Arch. Phys. Med. Rehabil. 86, 449-452 (2005)
80. Patnaik JL, Harmon H, Vogt RL. Follow-up of 2003 human West Nile virus infections, Denver, Colorado. Emerg. Infect. Dis. 12, 1129-1131.(2006).
81. Hayes EB, O'Leary DR. West Nile virus infection: a pediatric perspective. Pediatric 113, 1375-1381 (2004).
82. Carson PJ, Konewko P, Wold KS et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin. Infect. Dis. 43 723-730 (2006).
83. Murray KO, Resnick M, Miller V. Depression after infection with West Nile virus. Emerg. Infect. Dis. 13, 479-481 (2007).
84. Seth RK, Stoessel KM, Adelman RA, Choroidal neovascularization associated with West Nile Virus chorioretinitis. Semin. Ophthalmol. 22, 81-84 (2007).
85. Berner Y, Feldman J, Spigel D, Chowers M, Finckeltov B. Rehabilitation of West Nile fever (WNF) encephalitis it elderly. Arch. Gerontol. Geriatr. 41, 15-21 (2005).
86. Arroyo J, Miller C, Catalan J et al. ChimeriVax - West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol. 78, 12497-12507 (2004).
87. Hall RA, Khromykh AA. ChimeriVax - West Nile vaccine. Curr. Opin. Mol. Ther. 9, 498-504 (2007).
88. Monath TP, Liu J, Kanesa-Thasan N et al. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl Acad. Sci. USA 103, 6694-6699 (2006).
89. McDonald WF, Huleatt JW, Foellmer HG et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195, 1607-1617 (2007).
90. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 178, 2699-2705 (2007).
91. Throsby M, Ter Meulen J, Geuijen C, Goudsmit J, de Kruif J. Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development. Expert Rev. Vaccines 6(2), 183-191 (2007).